Bleeding and thrombosis in acute promyelocytic leukemia

Aditi Choudhry, Thomas Deloughery

    Research output: Contribution to journalArticle

    56 Citations (Scopus)

    Abstract

    Acute promyelocytic leukemia (APL) has evolved from being a deadly to a highly curable disease, due totargeted molecular therapy with all-trans retinoic acid (ATRA). As a result, the incidence of early hemorrhagic deaths for which APL is notorious has reduced to 5-10% as reported in clinical trials. These results are not replicated outside of clinical trials as is evident from recent population-based registries. High incidence of early hemorrhagic deaths remains the greatest contributor to treatment failure in this otherwise curable leukemia. Additionally, thrombosis is now being increasingly recognized in APL patients and may be associated with ATRA usage.

    Original languageEnglish (US)
    Pages (from-to)596-603
    Number of pages8
    JournalAmerican Journal of Hematology
    Volume87
    Issue number6
    DOIs
    StatePublished - Jun 2012

    Fingerprint

    Acute Promyelocytic Leukemia
    Thrombosis
    Hemorrhage
    Tretinoin
    Clinical Trials
    Incidence
    Treatment Failure
    Registries
    Leukemia
    Population
    Therapeutics

    ASJC Scopus subject areas

    • Hematology

    Cite this

    Bleeding and thrombosis in acute promyelocytic leukemia. / Choudhry, Aditi; Deloughery, Thomas.

    In: American Journal of Hematology, Vol. 87, No. 6, 06.2012, p. 596-603.

    Research output: Contribution to journalArticle

    @article{a07ce84ec2f6464587d861059f65844f,
    title = "Bleeding and thrombosis in acute promyelocytic leukemia",
    abstract = "Acute promyelocytic leukemia (APL) has evolved from being a deadly to a highly curable disease, due totargeted molecular therapy with all-trans retinoic acid (ATRA). As a result, the incidence of early hemorrhagic deaths for which APL is notorious has reduced to 5-10{\%} as reported in clinical trials. These results are not replicated outside of clinical trials as is evident from recent population-based registries. High incidence of early hemorrhagic deaths remains the greatest contributor to treatment failure in this otherwise curable leukemia. Additionally, thrombosis is now being increasingly recognized in APL patients and may be associated with ATRA usage.",
    author = "Aditi Choudhry and Thomas Deloughery",
    year = "2012",
    month = "6",
    doi = "10.1002/ajh.23158",
    language = "English (US)",
    volume = "87",
    pages = "596--603",
    journal = "American Journal of Hematology",
    issn = "0361-8609",
    publisher = "Wiley-Liss Inc.",
    number = "6",

    }

    TY - JOUR

    T1 - Bleeding and thrombosis in acute promyelocytic leukemia

    AU - Choudhry, Aditi

    AU - Deloughery, Thomas

    PY - 2012/6

    Y1 - 2012/6

    N2 - Acute promyelocytic leukemia (APL) has evolved from being a deadly to a highly curable disease, due totargeted molecular therapy with all-trans retinoic acid (ATRA). As a result, the incidence of early hemorrhagic deaths for which APL is notorious has reduced to 5-10% as reported in clinical trials. These results are not replicated outside of clinical trials as is evident from recent population-based registries. High incidence of early hemorrhagic deaths remains the greatest contributor to treatment failure in this otherwise curable leukemia. Additionally, thrombosis is now being increasingly recognized in APL patients and may be associated with ATRA usage.

    AB - Acute promyelocytic leukemia (APL) has evolved from being a deadly to a highly curable disease, due totargeted molecular therapy with all-trans retinoic acid (ATRA). As a result, the incidence of early hemorrhagic deaths for which APL is notorious has reduced to 5-10% as reported in clinical trials. These results are not replicated outside of clinical trials as is evident from recent population-based registries. High incidence of early hemorrhagic deaths remains the greatest contributor to treatment failure in this otherwise curable leukemia. Additionally, thrombosis is now being increasingly recognized in APL patients and may be associated with ATRA usage.

    UR - http://www.scopus.com/inward/record.url?scp=84861346428&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84861346428&partnerID=8YFLogxK

    U2 - 10.1002/ajh.23158

    DO - 10.1002/ajh.23158

    M3 - Article

    C2 - 22549696

    AN - SCOPUS:84861346428

    VL - 87

    SP - 596

    EP - 603

    JO - American Journal of Hematology

    JF - American Journal of Hematology

    SN - 0361-8609

    IS - 6

    ER -